FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Licensing Agreement

  • Home
  •  | 
  • Tag Archives: "Licensing Agreement"

Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon

Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon
Next Green Wave Holdings Inc. (CSE:NGW) (OTCQB:NXGWF) (“Next Green Wave”) and Intrexon Corporation (NASDAQ: XON) (“Intrexon”) are pleased to announce they have entered into a strategic licensing agreement to utilize Intrexon’s Botticelli™ next generation plant propagation platform to enable rapid production of Next Green Wave’s proprietary cannabis cultivars for the California market. The collaborative work conducted at Next Green Wave’s facilities will also accelerate its vision of becoming a world-class nursery.
Read more

Green Axis Announces Name Change, Board and Management Changes and Second Share Consolidation, Reflective of Market Value in Ignite Trademark and Licensing Agreement

Green Axis Announces Name Change, Board and Management Changes and Second Share Consolidation, Reflective of Market Value in Ignite Trademark and Licensing Agreement
Jan. 8, 2019 /CNW/ - Green Axis Capital Corp. (the "Company") today announces changes to its board of directors (the "Board") and executive management team, including the appointment of Dan Bilzerian as Chairman and CEO. In addition, the Company announces that it (i) is proposing to change its name to "Ignite International Brands, Ltd.", (ii) is proposing a second consolidation of all issued and outstanding common shares on a 5:1 basis and (iii) has reached an agreement with Ignite International, Ltd. (formerly Vulcan Enterprises US, Ltd.) ("Ignite US") to terminate the additional share exchange agreement that was announced by the Company on November 23, 2018.
Read more

CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement

CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement
CURE Pharmaceutical (OTC: CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year licensing agreement for the first time with a leading international cannabis company. Under the terms of the agreement, the cannabis company will have an exclusive license to CURE’s patented, multi-layer oral thin film (OTF), CUREfilm™ technology for use with cannabis extracts and biosynthetic cannabinoids in markets around the world. The parties will collaborate on new products and indications.
Read more